Quantum Biopharma Ltd. (NASDAQ:QNTM) Short Interest Update

Quantum Biopharma Ltd. (NASDAQ:QNTM) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totaling 67,767 shares, a decline of 44.5% from the November 30th total of 122,202 shares. Based on an average daily volume of 75,046 shares, the short-interest ratio is presently 0.9 days. Approximately 1.9% of the company’s stock are sold short. Approximately 1.9% of the company’s stock are sold short. Based on an average daily volume of 75,046 shares, the short-interest ratio is presently 0.9 days.

Institutional Trading of Quantum Biopharma

A hedge fund recently bought a new stake in Quantum Biopharma stock. Steward Partners Investment Advisory LLC acquired a new position in Quantum Biopharma Ltd. (NASDAQ:QNTM) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,100 shares of the company’s stock, valued at approximately $63,000. Steward Partners Investment Advisory LLC owned about 0.11% of Quantum Biopharma at the end of the most recent quarter. 1.24% of the stock is owned by institutional investors and hedge funds.

Quantum Biopharma Price Performance

Shares of QNTM stock opened at $8.30 on Friday. The firm has a 50-day moving average of $9.71 and a 200-day moving average of $16.26. Quantum Biopharma has a one year low of $2.89 and a one year high of $38.25. The company has a market cap of $31.71 million, a P/E ratio of -0.76 and a beta of 0.15.

Quantum Biopharma (NASDAQ:QNTM) last released its quarterly earnings results on Friday, November 7th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($1.05). As a group, research analysts expect that Quantum Biopharma will post -3.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on QNTM. Wall Street Zen upgraded Quantum Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Quantum Biopharma in a report on Monday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Quantum Biopharma presently has an average rating of “Sell”.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.